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Abstract
Several large randomized clinical trials in North America and Europe concluded over a decade ago
that carotid endarterectomy plus medical management was significantly better than medical
management alone for stroke prevention in either symptomatic or asymptomatic patients with severe
carotid stenosis. Percutaneous carotid angioplasty now represents another treatment option that
currently seems most appropriate either in the context of prospectively randomized trials or for
patients who are at a higher than average risk for conventional surgical treatment.
Introduction and context
Few modern clinical problems have provoked as much
controversy as extracranial carotid artery disease.
Prompted by concern that carotid endarterectomy
(CEA) was being performed for uncertain indications
during the 1980s, four randomized clinical trials (RCTs)
were sponsored by the National Institutes of Health in
the United States and by the Medical Research Council in
the United Kingdom in order to determine the benefit of
CEA in symptomatic patients and for asymptomatic
carotid stenosis [1–7]. These included the North Amer-
ican Symptomatic Carotid Endarterectomy Trial (NAS-
CET), the European Carotid Surgery Trial (ECST), the
Asymptomatic Carotid Atherosclerosis Study (ACAS)
and the Asymptomatic Carotid Surgery Trial (ACST), all
of which remain the foundation for proper patient
selection and should be thoroughly familiar to clinicians
who recommend or perform any kind of carotid
intervention.
Table 1 contains data from these four important
investigations. It must be noted that the methods for
estimating the percentage of carotid stenosis differed in
the North American (NASCET, ACAS) and the European
(ECST, ACST) trials; the former used the diameter of the
uninvolved internal carotid artery distal to the index
lesion as the denominator, whereas the latter employed
the projected normal diameter of the internal carotid
bulb. Nevertheless, the conclusions reached by these
trials were reasonably consistent and can be summarized
as follows.
First, the 30-day combined stroke or mortality rates for
CEA were two to three times higher in symptomatic
patients than in patients who had asymptomatic carotid
stenosis. This may reflect the potential of symptomatic
lesions to cause intraoperative cerebral emboli during
carotid manipulation.
Second, the benefit of CEA was greater and became
obvious within shorter periods of follow-up in patients
who had previous symptoms in conjunction with severe
carotid stenosis measuring at least 70% of lumen
diameter. The relative risk reduction associated with
CEA for 50–69% stenosis was only marginally significant
(P = 0.045) in the NASCET, and the ECST showed no risk
reduction at all for CEA in this particular group of
patients.
Third, in comparison to symptomatic patients in the
NASCET and ECST, patients with asymptomatic carotid
stenosis in the ACAS and the ACST had lower long-term
event rates irrespective of whether they were randomized
to CEA or medical management. Furthermore, while
CEA provided a significant overall reduction of relative
risk in the ACAS, this benefit seemed substantially less
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probably because they tended to have a higher incidence
of perioperative stroke or death (3.6 versus 1.7%,
P = 0.12).
Fourth, the ACST did not substantiate the apparent lesser
benefit of CEA that was found in asymptomatic women
by the ACAS, but this might be explained by the fact that
the ACST excluded the risk for perioperative stroke or
death (3.6% in women, 2.5% in men) from its subset
analyses. The ACST also reported that unoperated
patients with 60–79% stenosis were as likely as those
with 80–99% stenosis to have future strokes. The ACAS
did not further stratify its criterion of 60–99% stenosis,
but other non-randomized case series strongly suggest
that asymptomatic 60–79% stenosis has a very low risk
for stroke and can be kept under surveillance by duplex
scanning [8].
Fifth, the 'number needed to treat' (NNT) is defined as
the number of patients who would have to undergo CEA
in order to prevent one long-term adverse event. In the
NASCET, this ranged from an NNT of six for patients
who had 70–99% stenosis, to an NNT of 15 for patients
with 50–69% stenosis [1,2]. The corresponding NNT was
19 for all patients in the ACAS, and it undoubtedly was
even higher in women [6].
Recent advances
Percutaneous carotid angioplasty (PCA) was described in
isolated case reports during the late 1970s and has since
been the topic of more than 20 large case series, over a
dozen industry-sponsored registries, and a few indepen-
dent trials [9]. Many of these studies became obsolete
almost immediately because of additional refinements
in endovascular technology, such as carotid stents and
over-the-wire cerebral embolic protection devices [10].
Table 2 summarizes the results from four RCTs that were
published in peer reviewed journals [11–15] and
frequently have been cited on the basis of their
timeliness or their controversial aspects, depending on
the perspective from which they are viewed [16].
CAVATAS
Conducted from 1992 to 1997, the Carotid and Vertebral
Artery Transluminal Angioplasty Study (CAVATAS) was
the earliest trial of PCA versus CEA to be independently
funded and to capture international attention. Each of
the participating centers had to designate one or more
radiologists with prior training in angioplasty techni-
ques, but there was no requirement for previous
experience with the carotid artery. The CAVATAS showed
no long-term outcome differences between PCA and CEA
in symptomatic patients, but its credibility was eroded by
a 30-day stroke or mortality rate for CEA (9.9%) that was
much worsethan generally had been reported. Moreover,
carotid stents were used in only 26% of the patients who
received PCA, a factor that could have contributed to a
high incidence of recurrent ≥70% stenosis (18 versus
5.2% for CEA, P = 0.0001) at just 1 year of follow-up
[17]. Cerebral embolic protection devices were unavail-
able at that time, so this adjunct was not used in the
CAVATAS.
SAPPHIRE
The Stenting and Angioplasty with Protection in Patients
at High Risk for Endarterectomy (SAPPHIRE) trial was
funded by industry and for this reason may not have
quite the cache of an independent RCT. It enrolled
asymptomatic patients with ≥80% stenosis in addition to
symptomatic patients with ≥50% stenosis, and it
employed a unique primary end point of stroke, death
Table 1. Major RCTs in North America and Europe (1980s to mid-1990s) comparing carotid endarterectomy versus medical
management alone for stroke prevention
RCT Severity of
stenosis (%)
30-day surgical
CSM (%)
Reported
follow-up period
(years)
Long-term event rate Relative risk
reduction (%)
P-value
Carotid
endarterectomy (%)
Medical
management (%)
Symptomatic patients
NASCET [1] 70–99 5.8 2 9.0
a 26.0
a 65 <0.001
NASCET [2] 50–69 6.7 5 15.7
a 22.2
a 29 0.045
ECST [3] 70–99 7.5 3 12.3
b 21.9
b 45 <0.01
ECST [4,5] 50–69 7.9 8 18.4
b 15.6
b None -
Asymptomatic patients
ACAS [6] 60–99 2.3 5 5.1
a 11.0
a 53 0.004
ACST [7] 60–99 3.1 5 6.4
c 11.8
c 46 <0.0001
aIncludes 30-day strokes and deaths but only ipsilateral late strokes.
bIncludes 30-day strokes and deaths and all late strokes.
cIncludes 30-day strokes (but
not deaths) and all late strokes. ACAS, Asymptomatic Carotid Atherosclerosis Study; ACST, Asymptomatic Carotid Surgery Trial; CSM, combined stroke
and/or mortality rate; ECST, European Carotid Surgery Trial; NASCET, North American Symptomatic Carotid Endarterectomy Trial; RCT, randomized
controlled trial.
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departure from the traditional composite end point of
stroke and/or death, especially since it included asymp-
tomatic elevations in cardiac isoenzyme and troponin
levels that had not been measured in most previous
studies of CEA. The SAPPHIRE trial did have a number of
practical features, however. First, it only accepted
patients who were less than ideal surgical candidates
because of serious cardiac disease (e.g. recent MI or
unstable angina, congestive heart failure, <30% ejection
fraction) or treacherous local anatomy, such as high
carotid lesions near the skull base, prior cervical
irradiation, or recurrent stenosis after prior CEA. Second,
its interventionalists were strictly vetted and had a
median past experience with 64 PCAs. Third, every PCA
procedure in the trial was done using a cerebral embolic
protection device and a carotid stent, both of which were
manufactured by the sponsor (Cordis Corporation).
Much of the difference in 30-day end points could be
attributed to a higher incidence of 'chemical' MIs after
CEA, but the ultimate conclusion of the trial was that
PCA provided an equivalent alternative in patients who
were perceived to be at high risk for CEA. The SAPPHIRE
trial has been criticized on the grounds that the majority
(70%) of its patients were asymptomatic, that too many
were entered into a non-randomized PCA registry
because they were considered unsuitable for CEA, and
that the unconventional primary end points were
potentially misleading [18]. Asymptomatic carotid dis-
ease is the most common indication for CEA or PCA in
the United States [19], however, and not just for the
convincing severity of stenosis (80–99%) that this trial
required. In addition, participating surgeons may have
been understandably reluctant to randomize certain
patients who had multiple high-risk factors for CEA.
Finally, although the inclusion of clinically unsuspected
MIs was a novel approach to early outcome assessment,
it is difficult to argue logically that these events should
have been allowed to go undetected.
SPACE
The Stent-Supported Percutaneous Angioplasty of the
Carotid Artery versus Endarterectomy (SPACE) trial is a
non-inferiority study that was designed to demonstrate
equivalence between PCA/stenting and CEA. In order to
participate, interventionalists had to show proof of at
least 25 successful consecutive PCA procedures. The
virtues of the SPACE trial are its large size (1,200
symptomatic patients), which thusfar exceeds any
similar RCT, and the fact that it has been supported
predominantly by independent resources. Its perceived
liabilities are that cerebral embolic protection was used
during only 27% of the PCA procedures, and that
recruitment was prematurely stopped for lack of funding
after it was discovered that more than 2,500 patients
would be necessary to confirm its interim results with
adequate statistical power. At that time, the 30-day risk
for death or ipsilateral stroke appeared comparable for
PCA and CEA (6.8 and 6.3%, respectively), but the
P-value for non-inferiority was only 0.9. No long-term
event rates are available for the SPACE trial, but its
trialists have stated that these outcomes will be
published in the form of a meta-analysis in conjunction
with other European RCTs [14].
EVA-3S
The Endarterectomy Versus Angioplasty in Patients with
Symptomatic Severe Carotid Stenosis (EVA-3S) trial is
the most recent study summarized in Table 2 and could
conceivably serve as a proxy for the evolution of PCA in
other large population bases. Sponsored by the French
Table 2. Selected data from recent RCTs comparing carotid endarterectomy to percutaneous
carotid angioplasty
RCT Clinical features Angioplasty adjuncts 30-day surgical or procedural CSM Long-term event rate
Symptoms (%) Stenosis (%) Stent (%) CEP (%) CEA (%) PCA (%) P-value CEA (%) CA (%) P-value
CAVATAS [11] 97 Mean: 85±10 26 None 9.9 10 NS 14.2
a 14.3
a NS
SAPPHIRE
b [12,13] 29 ≥50 (symptomatic) 100 100 9.8
c 4.8
c 0.09 26.9
d 24.6
d 0.71
≥80 (asymptomatic)
SPACE [14] 100 ≥50 (NASCET) 100 27 6.3
e 6.8
e 0.09 NR NR -
≥70 (ECST)
EVA-3S [15] 100 ≥60 100 92 3.9
f 9.6
f 0.01 4.2
g 10.2
g 0.008
aDeath or disabling stroke within 3 years.
bIndustry sponsored (Cordis Corporation).
cDeath, stroke or myocardial infarction.
dDeath, stroke or myocardial
infarction within 30 days or death or ipsilateral stroke within 3 years.
eDeath or ipsilateral ischemic stroke.
fAny death or stroke.
gAny death or stroke
within 30 days plus ipsilateral stroke between 31 days and 6 months. CAVATAS, Carotid and Vertebral Artery Transluminal Angioplasty Study; CEA, carotid
endarterectomy; CEP, cerebral embolic protection; CSM, combined stroke and/or mortality rate; EVA-3S, Endarterectomy Versus Angioplasty in Patients
with Symptomatic Severe Carotid Stenosis trial; NR, not reported; NS, not significant; PCA, percutaneous carotid angioplasty; RCT, randomized controlled
trial; SAPPHIRE, Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy trial; SPACE, Stent-Supported Percutaneous
Angioplasty of the Carotid Artery versus Endarterectomy trial.
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medical centers, this trial permitted the use of a variety of
approved catheter devices. Carotid stenting was manda-
tory, but cerebral embolic protection (ultimately used in
92% of patients) was not routinely recommended until
the 30-day stroke rate was discovered to be 3.9 (95%
confidence interval, 0.9 to 16.7) times higher without
embolic protection (27%, 4 out of 15) than with
protection (8.6%, 5 out of 58) in the initial 73 patients
treated by PCA [20]. Perhaps the most controversial
element of this trial is that interventionalists who had no
previous experience with PCA still were permitted to
perform it in randomized patients under the supervision
of tutors until they acquired the requisite number of 12
PCAs (or only five PCAs plus another 30 stenting
procedures in aortic arch vessels) for full accreditation.
Interventionalists also could begin using a new catheter
device within the trial as soon as they had gained some
familiarity with it in just two other cases.
Trial enrollment was stopped on the basis of safety and
futility once the 30-day stroke or mortality rate in the first
527 treated patients was found to be so much higher for
PCA (9.6 versus 3.9% for CEA; relative risk, 2.5; 95%
confidence interval, 1.2 to 5.1; P = 0.01) that more than
4,000 patients would have been necessary to demon-
strate its non-inferiority to CEA. The EVA-3S trial has
been criticized for the inexperience among its interven-
tionalists and the lack of a standardized technique for
PCA, but the flaws that some might find in this trial - the
mix of community hospitals as well as referral centers,
the mid-course changes to new or improved equipment,
the low procedural volumes or on-the-job training by
more experienced colleagues - are ubiquitous and may
make its results more relevant to 'real world' practice
[21]. The French trial was limited to symptomatic
patients, but another national dataset also has shown
that PCA/stenting was associated with higher risks for
stroke or death than CEA in both symptomatic and
asymptomatic patients in the United States during 2003
and 2004 [19].
Ongoing trials
The International Carotid Stenting Study (ICSS), or
CAVATAS 2, and the Carotid Revascularization Endarter-
ectomy versus Stent Trial (CREST) are two major
independent RCTs currently underway in Europe and
North America, respectively. No outcome data are
available from the ICSS, but the CREST has reported
early results for a total of 749 patients who underwent
PTA/stenting with routine embolic protection during a
lead-in phase that was used to credential intervention-
alists. The 30-day stroke or mortality rate was signifi-
cantly higher (12%, P < 0.0001) in octogenarians than it
was in patients who were 70 to 79 (5.3%), 60 to 69
(1.3%) or less than 60 (1.7%) years of age [22]. Others
have confirmed the unfavorable influence of advancing
age on the risk of PCA in device regulatory trials [23] and
have attributed this to the arterial tortuosity and
calcification that often occur in elderly patients, thus
making catheter-directed devices more likely to provoke
cerebral emboli [24].
Implications for clinical practice
Citing much of the material covered in this review as well
as additional sources in the literature, the Society for
Vascular Surgery recently published clinical practice
guidelines for the management of atherosclerotic carotid
artery disease [25]. This document reconfirms the
continued importance of the NASCET, ECST, ACAS and
ACST in the selection of patients for either surgical or
catheter-based intervention, emphasizing that patients
who have symptomatic <50% stenosis or asymptomatic
<60% stenosis are well suited to optimal medical
management alone. These guidelines also propose that
CEA plus medical therapy should remain the primary
option for patients with more severe stenosis unless the
ICSS and the CREST eventually prove otherwise. On the
basis of current uncertainties, PCA generally seems most
appropriate in the setting of these or similar trials until it
has been shown conclusively to have the same safety and
durability as CEA. In the meantime, exceptions favoring
PCA can be justified for patients whose medical
comorbidities or cervical anatomy make them question-
able candidates for CEA.
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